Key Points
- Director Gregory George's purchases: George bought 1,586,890 shares on April 9 at $1.44 ( ~$2.29M), increasing his stake to 13,586,890 shares, and has made several recent buys (Apr 4, Apr 9, Apr 10) that total roughly $28.4M.
- Stock and fundamentals snapshot: MESO was trading down ~2%, has a $1.90B market cap and negative earnings (reported -$0.16 EPS last quarter; analysts forecast ~-0.70 EPS for the year), with a consensus rating of "Hold" and mixed analyst views.
Mesoblast Limited (NASDAQ:MESO - Get Free Report) Director Gregory George bought 1,586,890 shares of the firm's stock in a transaction dated Thursday, April 9th. The stock was acquired at an average cost of $1.44 per share, with a total value of $2,285,121.60. Following the transaction, the director owned 13,586,890 shares of the company's stock, valued at $19,565,121.60. This trade represents a 13.22% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Gregory George also recently made the following trade(s):
- On Friday, April 10th, Gregory George purchased 2,324,072 shares of Mesoblast stock. The shares were acquired at an average cost of $1.48 per share, for a total transaction of $3,439,626.56.
- On Thursday, April 9th, Gregory George acquired 1,981,890 shares of Mesoblast stock. The stock was acquired at an average cost of $8.59 per share, with a total value of $17,024,435.10.
- On Saturday, April 4th, Gregory George acquired 4,000,000 shares of Mesoblast stock. The shares were acquired at an average price of $1.42 per share, with a total value of $5,680,000.00.
Mesoblast Trading Down 2.0%
NASDAQ:MESO opened at $14.70 on Tuesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.58 and a quick ratio of 1.41. Mesoblast Limited has a fifty-two week low of $9.88 and a fifty-two week high of $21.50. The stock's 50-day moving average is $15.60 and its two-hundred day moving average is $16.80. The stock has a market cap of $1.90 billion, a PE ratio of -27.22 and a beta of 2.19.
Mesoblast (NASDAQ:MESO - Get Free Report) last posted its quarterly earnings results on Thursday, January 29th. The company reported ($0.16) earnings per share (EPS) for the quarter. The firm had revenue of $25.67 million for the quarter. As a group, equities research analysts forecast that Mesoblast Limited will post -0.7 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Mesoblast
A number of hedge funds have recently added to or reduced their stakes in MESO. Caitong International Asset Management Co. Ltd bought a new position in shares of Mesoblast in the fourth quarter valued at approximately $32,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Mesoblast by 30.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,383 shares of the company's stock valued at $43,000 after purchasing an additional 558 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Mesoblast by 55.6% in the third quarter. JPMorgan Chase & Co. now owns 2,831 shares of the company's stock valued at $46,000 after purchasing an additional 1,012 shares in the last quarter. JFS Wealth Advisors LLC bought a new position in Mesoblast in the third quarter worth $54,000. Finally, Farther Finance Advisors LLC bought a new position in Mesoblast in the third quarter worth $58,000. Institutional investors and hedge funds own 1.43% of the company's stock.
Analyst Ratings Changes
Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Mesoblast in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Mesoblast currently has a consensus rating of "Hold".
View Our Latest Analysis on MESO
Mesoblast Company Profile
(
Get Free Report)
Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.
The company's most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn's disease.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
